Telomir-1 / Telomir Pharmaceuticals - LARVOL DELTA

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells (ACCESS Newswire) - "In an in vitro study conducted by SmartAssays, LNCaP prostate cancer cells were stimulated with dihydrotestosterone (DHT), a potent androgen that increases PSA production. Under these conditions, Telomir-1 produced a concentration-related reduction in PSA release, paralleling its inhibitory effects on cellular energy metabolism and cell viability....The PC3 model represents an androgen-independent tumor type, meaning the cancer cells no longer rely on hormones like testosterone to grow and are generally more aggressive and treatment-resistant."

Preclinical • Prostate Cancer

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells (ACCESS Newswire) - "In this study, HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity in this aggressive human model....Findings expand Telomir-1's oncology profile into cancers of the blood..."

Preclinical • Leukemia

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line (ACCESS Newswire) - "HaCaT cells were incubated with Telomir-1 or DFO for various time points. After three, six and sixteen hours, fluorescence microscopy revealed a markedly lower intracellular iron signal in Telomir-1-treated cells, indicating strong cell penetration and iron-modulating capacity relative to DFO at the same concentrations."

Preclinical • Oncology

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo (ACCESS Newswire) - "When Telomir-1 was administered with chemotherapy, both CASP8 and GSTP1 showed lower methylation than with chemotherapy alone, suggesting that Telomir-1 may help counteract chemotherapy related epigenetic silencing in this setting."

Preclinical • Prostate Cancer

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer (ACCESS Newswire) - "In laboratory studies using human pancreatic cancer (PANC-1) cells, Telomir-1 produced a concentration-dependent reduction in cancer cell survival and mitochondrial activity. These data suggest Telomir-1 influences cellular pathways related to energy metabolism and oxidative balance...Telomir-1's effects in pancreatic-cancer cells were partially reversed by iron re-addition....The incomplete reversal supports the interpretation that additional metabolic or epigenetic mechanisms are also engaged."

Preclinical • Pancreatic Cancer

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model… (ACCESS Newswire) - "Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models."

Preclinical • Prostate Cancer

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells (ACCESS Newswire) - "...New findings demonstrating that Telomir-1 significantly decreases the viability of aggressive triple-negative breast cancer (TNBC) cells - a highly invasive form of breast cancer that lacks hormone and HER2 receptors, offers limited treatment options, and carries one of the poorest survival rates among breast cancer subtypes."

Preclinical • Triple Negative Breast Cancer

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy (ACCESS Newswire) - "In aggressive human prostate cancer cell models (PC3 xenografts), Telomir-1 inhibited CDKN2A DNA methylation more effectively than both Rapamycin and chemotherapy. These results complement Telomir's previously reported data showing that Telomir-1 also resets STAT1, a master regulator of immune surveillance."

Preclinical • Prostate Cancer

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin (ACCESSWIRE) - "Telomir Pharmaceuticals...announced compelling new preclinical findings highlighting Telomir-1's ability to reverse epigenetic gene silencing in aggressive human prostate cancer cells-achieving greater efficacy than Paclitaxel and Rapamycin in restoring the STAT1 tumor suppressor....In this newly reported study, Telomir-1 administered orally over 21 days in a mouse model implanted with aggressive human prostate cancer cells (PC3 xenograft) fully reversed this hypermethylation in a dose-dependent fashion. In contrast, Paclitaxel (PTX) showed no effect, and Rapamycin achieved only partial reduction of hypermethylation of STAT1....This mechanism offers a potential explanation for the tumor shrinkage observed by Telomir-1 and highlights a biological pathway not addressed by standard chemotherapy."

Preclinical • Prostate Cancer

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints (ACCESSWIRE) - "Following a 14-day oral dosing regimen, Telomir-1 reversed central vision response and vision acuity, restored retinal degeneration and architecture, and significantly reduced oxidative stress-achieving improvements across several FDA-recognized surrogate endpoints relevant to AMD....Histological cross-sections confirmed Telomir-1's ability to regenerate not only the inner retinal layers, but also additional retinal structures-supporting improved-laminar retinal restoration and function. Collectively, these results demonstrate Telomir-1's ability to restore visual function, reverse retinal degeneration, reduce oxidative stress, and improve survival-all from a short oral treatment regimen."

Preclinical • Age-related Macular Degeneration

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells (ACCESSWIRE) - "Telomir Pharmaceuticals...announced groundbreaking preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive human prostate cancer cells....Key findings include: (i) Telomir-1 alone at both low and high doses reduced tumor growth by approximately 50%; (ii) Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 demonstrated the opposite effect-actively suppressing tumor development, while selectively benefiting healthy cells; (iii) In the group treated with Paclitaxel alone, severe toxicity was observed, leading to significant weight loss and mortality of one-third of the animals. However, when low-dose Telomir-1 was added to Paclitaxel, no mortality occurred....The company is prioritizing the fastest pathway to clinical trials and aims to submit its Investigational New Drug (IND) application by year-end."

IND • Preclinical • Prostate Cancer